Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
Diabetes Care2014Vol. 38(3), pp. 403–411
Citations Over TimeTop 1% of 2014 papers
Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews, on behalf of the CANVAS Trial Collaborative Group
Abstract
Canagliflozin added to insulin therapy improved glycemic control and decreased body weight. There was a greater frequency of several anticipated side effects, although few led to discontinuation of treatment.
Related Papers
- → Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients(2018)17 cited
- → Abstract #262 Effects of Canagliflozin (CANA) On Hba1c and Changes in AHAS in the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program(2018)2 cited
- → Canagliflozin(2014)1 cited
- → PDB64 COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE(2019)
- → A real-world retrospective evaluation of glycaemic control and weight loss in patients with type 2 diabetes mellitus treated with canagliflozin 100 mg and canagliflozin 300 mg in an Indian setting(2020)